Financial Architects (New Jersey)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Financial Architects (New Jersey)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-380	Closed	-$20K	–	1581
2017 Q3	$20K	Hold	380	–	–	﹤0.01%	960
2017 Q2	$24K	Sell	380 -1,000	-72%	-$60.2K	﹤0.01%	908
2017 Q1	$94K	Hold	1,380	–	–	0.02%	490
2016 Q4	$97K	Hold	1,380	–	–	0.02%	401
2016 Q3	$98K	Hold	1,380	–	–	0.03%	401
2016 Q2	$67K	Hold	1,380	–	–	0.02%	472
2016 Q1	$87K	Buy	+1,380	New	+$90.3K	0.03%	303
2015 Q3	–	Sell	-1,380	Closed	-$141K	–	745
2015 Q2	$141K	Hold	1,380	–	–	0.05%	243
2015 Q1	$86K	Buy	+1,380	New	+$76.7K	0.03%	311

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Financial Architects (New Jersey)'s RARE Position: Q4 2017 in Review

Financial Architects (New Jersey) sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 380 shares — an estimated $20K sold.

Financial Architects (New Jersey) first reported a position in RARE in Q1 2015 and held it in 9 quarters. The position peaked at $141K in Q2 2015. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

Financial Architects (New Jersey) reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
Financial Architects (New Jersey) sold 380 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $20K.
Financial Architects (New Jersey) first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 9 quarters.
Financial Architects (New Jersey)'s Ultragenyx Pharmaceutical position peaked at $141K in Q2 2015.
163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2017, filed 12 Feb 2018.